GSA Capital Partners LLP Acquires 78,827 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

GSA Capital Partners LLP lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 70.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 190,294 shares of the biotechnology company’s stock after purchasing an additional 78,827 shares during the quarter. GSA Capital Partners LLP owned about 0.09% of BioCryst Pharmaceuticals worth $1,444,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BCRX. Farther Finance Advisors LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 8,109 shares during the period. State of Alaska Department of Revenue bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $90,000. MQS Management LLC acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter worth $99,000. Inceptionr LLC bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth about $107,000. Finally, Choreo LLC bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth about $121,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the transaction, the insider owned 398,751 shares of the company’s stock, valued at $3,050,445.15. The trade was a 5.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 183,453 shares of company stock valued at $1,330,965. 5.10% of the stock is currently owned by corporate insiders.

BioCryst Pharmaceuticals Trading Up 2.8%

Shares of BCRX opened at $6.95 on Wednesday. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -139.00 and a beta of 0.83. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The company’s fifty day simple moving average is $7.10 and its 200 day simple moving average is $7.43.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Barclays decreased their price objective on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Citizens Jmp reduced their price target on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada lowered their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Finally, Needham & Company LLC decreased their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.82.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.